VERRICA PHARMACEUTICALS INC.

(VRCA)
  Report
Delayed Nasdaq  -  04:00 2022-07-05 pm EDT
2.500 USD   +15.21%
05:44pVERRICA PHARMACEUTICALS : Statement of Changes in Beneficial Ownership (Form 4)
PU
04:20pINSIDER BUY : Verrica Pharmaceuticals
MT
07/01VERRICA PHARMACEUTICALS : Announces Proposed Public Offering of Common Stock - Form 8-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Verrica Pharmaceuticals Shares Plumb New Depths After VP-102 Setback

05/25/2022 | 11:05am EDT

By Colin Kellaher


Shares of Verrica Pharmaceuticals Inc. plunged more than 50% and hit a new all-time low on Wednesday after the dermatology therapeutics company's latest setback in its bid to win regulatory approval for its lead drug candidate.

Verrica late Tuesday said the U.S. Food and Drug Administration again turned away its application for VP-102 for the skin disease molluscum contagiosum due to problems at the contract manufacturing plant where the drug is made in bulk.

The FDA initially rejected Verrica's application for VP-102 in July 2020, asking for additional details on some aspects of the company's chemistry, manufacturing and controls process and human factors validation.

The agency again rejected Verrica's application last September, in part due to issues identified during an inspection of the contract manufacturing plant, owned by privately-held Sterling Pharmaceuticals Services LLC.

Verrica said it believed the issues had been resolved to the FDA's satisfaction when it resubmitted its application in November, but the company on Tuesday said an FDA reinspection of the plant found deficiencies that resulted in Sterling being placed on "Official Action Indicated" status, meaning the agency will recommend regulatory and/or administrative actions.

Verrica said that the FDA, in its complete response letter indicating that the agency won't approve the VP-102 application in its current form, didn't identify any deficiencies other than those at the Sterling plant and that none of the issues the FDA found during reinspection were specific to the manufacturing of VP-102.

The West Chester, Pa., company said that the FDA had no open questions on its review of the application and was ready to communicate the VP-102 label, but that agency policy prevents it from communicating a label and approving a drug when a contract manufacturing organization is on Official Action Indicated status.

Following the latest setback, analysts Gregory Renza and Yinglu Zhang at RBC Capital Markets lowered their recommendation on Verrica shares to sector perform from outperform and cut their price target on the shares to $4 from $16, saying they are moving to the sidelines as they await clarity on a new path to approval.

Verrica said it is working to help Sterling address the issues the FDA identified, and that it is also engaging another contract manufacturing organization as an alternative supplier of VP-102's bulk solution.

The company also said PBM Capital, a healthcare-focused investment firm run by Paul Manning, Verrica's chairman and largest shareholder, has expressed its continued support and that it is confident it will have access to adequate capital to fund its operations through the potential approval of VP-102 for molluscum, a highly contagious viral skin disease for which there are currently no FDA-approved treatments.

The RBC analysts said while an attractive molluscum end-market awaits VP-102, they expect a relatively longer timeline toward potential deficiency resolution and resubmission of the application given the greater severity of issues at Sterling and the potential switch to a new supplier.

Verrica shares were recently changing hands at $2.23, down nearly 60%, after falling to $2.20--their lowest level since the company went public in June 2018--early in the session.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

05-25-22 1104ET

Stocks mentioned in the article
ChangeLast1st jan.
BRITISH POUND / AUSTRALIAN DOLLAR (GBP/AUD) -0.28% 1.75762 Delayed Quote.-4.71%
BRITISH POUND / CANADIAN DOLLAR (GBP/CAD) 0.01% 1.55732 Delayed Quote.-8.78%
BRITISH POUND / JAPANESE YEN (GBP/JPY) -1.33% 162.36 Delayed Quote.4.88%
BRITISH POUND / NEW ZEALAND DOLLAR (GBP/NZD) -0.63% 1.93699 Delayed Quote.-1.43%
BRITISH POUND / SWISS FRANC (GBP/CHF) -0.54% 1.1575 Delayed Quote.-6.05%
BRITISH POUND / US DOLLAR (GBP/USD) -1.28% 1.1958 Delayed Quote.-10.57%
EURO / BRITISH POUND (EUR/GBP) -0.29% 0.85861 Delayed Quote.2.62%
VERRICA PHARMACEUTICALS INC. 15.21% 2.5 Delayed Quote.-76.31%
All news about VERRICA PHARMACEUTICALS INC.
05:44pVERRICA PHARMACEUTICALS : Statement of Changes in Beneficial Ownership (Form 4)
PU
04:20pINSIDER BUY : Verrica Pharmaceuticals
MT
07/01VERRICA PHARMACEUTICALS : Announces Proposed Public Offering of Common Stock - Form 8-K
PU
07/01VERRICA PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Other Events, F..
AQ
06/30VERRICA PHARMACEUTICALS, INC. COMPAN : Berger Montague Investigates Securities Fraud Alleg..
PR
06/30Verrica Pharmaceuticals Prices $25.2 Million Common Stock Offering
MT
06/29Verrica Announces Pricing of Public Offering of Common Stock
GL
06/29VERRICA PHARMACEUTICALS : Company Presentation
PU
06/29Verrica Pharmaceuticals Plans Common Stock Offering; Shares Plunge After-Hours
MT
06/29Verrica Announces Proposed Public Offering of Common Stock
GL
More news
Analyst Recommendations on VERRICA PHARMACEUTICALS INC.
More recommendations
Financials (USD)
Sales 2022 1,08 M - -
Net income 2022 -36,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,13x
Yield 2022 -
Capitalization 85,8 M 85,8 M -
Capi. / Sales 2022 79,7x
Capi. / Sales 2023 8,98x
Nbr of Employees 38
Free-Float 27,1%
Chart VERRICA PHARMACEUTICALS INC.
Duration : Period :
Verrica Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERRICA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 2,50 $
Average target price 10,25 $
Spread / Average Target 310%
EPS Revisions
Managers and Directors
Ted White President, Chief Executive Officer & Director
Terry Kohler Chief Financial & Accounting Officer
Paul B. Manning Chairman
Gary Goldenberg Chief Medical Officer
Eugene Scavola Executive Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
VERRICA PHARMACEUTICALS INC.-76.31%86
JOHNSON & JOHNSON4.94%472 389
PFIZER, INC.-11.41%293 506
ELI LILLY AND COMPANY17.55%292 291
ROCHE HOLDING AG-14.90%274 360
ABBVIE INC.13.59%271 782